Whitepapers

Pan-European Joint HTA: What does the future hold for innovative therapies?

In January 2018, the European Commission released a legislative proposal on Health Technology Assessment (HTA) with the overarching goal to strengthen cooperation among national HTA authorities in the European Union (EU). 

Under the EU HTA Regulation, manufacturers of health technologies will be obliged to submit a HTA dossier for certain medicinal products for joint clinical assessment (JCA). 

After over 3 years of discussion, the final adoption of the policy is drawing near, with the European Parliament and Council reaching a political agreement on the regulation in June 2021. 

What is the EU HTA Regulation trying to tackle?

Currently, HTAs are largely conducted at national and regional level by individual EU Member States with different evidence requirements and methodologies employed by HTA authorities.

Please enter your details in the form on the right to download the full text

Register to download whitepaper

Please enter your details if you want to download the full whitepaper.






    Share post

    Share on facebook
    Share on twitter
    Share on linkedin
    Share on whatsapp
    Share on email